WHO ICTRP trial
OS Study of Pembrolizumab (MK-3475) vs. SOC in Treatment Naïve Subjects with…
EUCTR2014-001473-14-SE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2014-001473-14-SE |
|---|---|
| Public title | OS Study of Pembrolizumab (MK-3475) vs. SOC in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic NSCLC (Keynote 042) |
| Scientific title | A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042) - OS study of Pembrolizumab vs. SOC in 1L subjects with… |
| Primary sponsor | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | Portugal;Philippines;Hong Kong;Taiwan;Estonia;Thailand;Ukraine;Chile;Russian Federation;Colombia;Switzerland;Vietnam;Malaysia;Peru;South Africa;Latvia;China;Korea, Republic… |
| Conditions | Non-Small Cell Lung Carcinoma;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Product Name: MK-3475; SCH900475; pembrolizumab Product Code: MK-3475; SCH900475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: pembrolizumab CAS Number: 1374853-91-4 Current Sponsor code: MK-3475 Other descriptive name… |
| Registration date | Jul 24, 2014 |
| Target size | 1250 |
| Secondary IDs | MK-3475-042 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: